Drug Profile
PT 107
Alternative Names: PT-107Latest Information Update: 25 Sep 2019
Price :
$50
*
At a glance
- Originator Pique Therapeutics
- Developer Pique Therapeutics; Technomark Life Sciences
- Class Antineoplastics; Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 25 Sep 2019 No development reported - Phase-II for Non-small cell lung cancer in USA, India (Intradermal)
- 07 Nov 2017 Positive efficacy and adverse events data from a phase II trial in non-small cell lung cancer released by Pique Therapeutics
- 23 Jun 2015 Phase-II ongoing for non-small cell lung cancer in USA and India